Audiological assessment before and after fractionated stereotactic irradiation for vestibular schwannoma

被引:0
|
作者
Sakamoto, T
Shirato, H [1 ]
Sato, N
Kagei, K
Sawamura, Y
Suzuki, K
Takizawa, H
Hokunan, K
Isu, T
Fukuda, S
Inuyama, Y
Miyasaka, K
机构
[1] Hokkaido Univ, Sch Med, Dept Radiol, Sapporo, Hokkaido 0608638, Japan
[2] Hokkaido Univ, Sch Med, Dept Otolaryngol, Sapporo, Hokkaido 060, Japan
[3] Hokkaido Univ, Sch Med, Dept Neurosurg, Sapporo, Hokkaido 060, Japan
[4] Obihiro Kohsei Hosp, Dept Radiol, Obihiro, Hokkaido, Japan
[5] Obihiro Kohsei Hosp, Dept Otolaryngol, Obihiro, Hokkaido, Japan
[6] Dept Otolaryngol, Kushiro, Japan
[7] Dept Neurosurg, Kushiro, Japan
关键词
stereotactic irradiation; stereotactic radiotherapy; stereotactic boost; vestibular schwannoma; acoustic neuroma;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To find the audiological outcome after LINAC-based fractionated stereotactic irradiation (STI). Materials and methods: Twenty-four patients with vestibular schwannoma treated by fractionated STI between 1991 and 1997 had measurable hearing before STI and were followed audiologically for more than 6 months. The pure tone average (PTA) was measured by averaging the air-conduction threshold for five main frequencies (250-4000 Hz) before and periodically after STI in the 24 patients. Several possible prognostic factors for hearing preservation (defined as a PTA change at the last follow-up of less than 10 dB) were investigated. The median follow-up time was 22 months, ranging from 5 to 69 months. The irradiation schedule was 36 Gy in 20 fractions in 5 weeks to 44 Gy in 22 fractions in 6 weeks followed by 4 Gy/1 fraction boost. Results: The pure tone average before STI was distributed from 7 to 73 dB. Fifty percent of patients showed a change in PTA of less than 10 dB, 79.2% of patients showed a change in PTA of less than 20 dB and 20.8% of patients showed a change in PTA of more than 21 dB at the last follow-up. Only one patient (4%) became deaf. Cases with a sudden loss of hearing were more likely to experience hearing preservation than those with gradual loss of hearing (P < 0.05). The mean age was younger in patients whose hearing was preserved (P < 0.05). Poor pretreatment PTA appeared to linearly correspond to the changes in PTA (regression coefficient 0.78). The size of the tumor was not related to the change in PTA. No relationship was observed between the maximum or peripheral dose and the PTA change. The real benefit of stereotactic boost after small-field fractionated irradiation was not certain. Conclusion: Fractionated STI produced a hearing preservation rate compatible with meticulously collimated multi-spots single fraction irradiation. Further follow-up is required to confirm the long-term benefits of fractionation. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:185 / 190
页数:6
相关论文
共 50 条
  • [1] Annual rate of hearing loss falls after fractionated stereotactic irradiation for vestibular schwannoma
    Sakamoto, T
    Shirato, H
    Takeichi, N
    Aoyama, H
    Fukuda, S
    Miyasaka, K
    [J]. RADIOTHERAPY AND ONCOLOGY, 2001, 60 (01) : 45 - 48
  • [2] Radiosurgery and fractionated stereotactic radiotherapy of vestibular schwannoma
    Hamm, K.
    Herold, H-U.
    Surber, G.
    Rosahl, S.
    [J]. HNO, 2017, 65 (05) : 434 - 441
  • [3] Medication for hearing loss after fractionated stereotactic radiotherapy (SRT) for vestibular schwannoma
    Sakamoto, T
    Shirato, H
    Takeichi, N
    Aoyama, H
    Kagei, K
    Nishioka, T
    Fukuda, S
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 50 (05): : 1295 - 1298
  • [4] Long-term follow-up results with audiological assessment after fractionated stereotactic radiotherapy for vestibular schwannomas
    Sawamura, Y
    Shirato, H
    Sakamoto, T
    Aoyama, H
    Fukuda, S
    Miyasaka, K
    [J]. ACOUSTIC NEUROMA: CONSENSUS ON SYSTEMS FOR REPORTING RESULTS, 2003, 10 : 127 - 128
  • [5] Fractionated Stereotactic Radiotherapy for Vestibular Schwannoma. Toxicity and Complications
    Perez Montero, H.
    Gascon, N.
    Guardado, S.
    Cabezas, A.
    D'Ambrosi, R.
    Rodriguez, V.
    Perez-Regadera, J.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S683 - S683
  • [6] What is the demand for audiological and vestibular rehabilitation after surgery for vestibular schwannoma?
    Baguley, DM
    Stoddart, RL
    Moffat, DA
    [J]. THIRD INTERNATIONAL CONFERENCE ON ACOUSTIC NEURINOMA AND OTHER CPA TUMORS, 1999, : 1101 - 1105
  • [7] Stereotactic Radiosurgery (SRS) for Vestibular Schwannoma: Longitudinal Audiologic Assessment in Single and Fractionated Treatments.
    Khattab, M. H.
    Wharton, D. M.
    Kim, E.
    Chambless, L. B.
    Weaver, K.
    Luo, G.
    Yock, A.
    Morales, M.
    Cmelak, A. J.
    Attia, A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E272 - E272
  • [8] Stereotactic fractionated radiotherapy and LINAC-Radiosurgery in the treatment of vestibular schwannoma
    Ladar, C
    Grosu, A
    Oestreicher, E
    Müller, A
    Arnold, A
    Molls, M
    [J]. RADIOTHERAPY AND ONCOLOGY, 2004, 71 : S11 - S11
  • [9] Predictive Factors of Pseudoprogression in Vestibular Schwannoma Treated with Fractionated Stereotactic Radiotherapy
    Lo, A. W. S.
    Nyaw, S. F.
    Mui, W. H.
    Huang, J. J.
    Kam, K. M.
    Wong, C. S.
    [J]. HONG KONG JOURNAL OF RADIOLOGY, 2019, 22 (03): : 152 - 159
  • [10] Stereotactic fractionated radiotherapy and LINAC-radiosurgery in the treatment of vestibular schwannoma
    Ladar, C
    Grosu, A
    Fauser, C
    Oestreicher, E
    Pinsker, K
    Jaeger, R
    Staerk, S
    Arnold, W
    Lumenta, C
    Molls, M
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S313 - S314